Table 1 Comparison of baseline clinical characteristics and treatment response between HBeAg-positive patients with and without hepatic steatosis (HS)
Overall population | Age/gender-matched subgroups | ||||||
|---|---|---|---|---|---|---|---|
Total | HS (−) | HS (+) | p | HS (−) | HS (+) | p | |
No | 196 | 94 | 102 | 56 | 56 | ||
Age at treatment, year | 39.6 ± 11.2 | 36.2 ± 10.8 | 42.7 ± 10.8 | < 0.001 | 38.5 (31–44) | 39 (31–44) | 0.930 |
Male | 142 (72.4) | 61 (64.9) | 81 (79.4) | 0.035 | 43 (76.8) | 43 (76.8) | 1.000 |
BMI, kg/m2 | 24.0 ± 3.2 | 22.7 ± 2.8 | 25.2 ± 3.1 | < 0.001 | 23.0 ± 3.0 | 25.0 ± 3.0 | 0.003 |
Genotype | 0.004 | 0.087 | |||||
B | 100 (53.5) | 60 (64.5) | 40 (42.6) | 35 (62.5) | 23 (44.2) | ||
C | 87 (46.5) | 33 (35.5) | 54 (57.4) | 21 (37.5) | 29 (55.8) | ||
Treatment-naïve | 159 (81.1) | 77 (81.9) | 82 (80.4) | 0.929 | 43 (76.8) | 45 (80.4) | 0.818 |
Cirrhosis | 59 (30.1) | 19 (20.2) | 40 (39.2) | 0.006 | 13 (23.2) | 17 (30.4) | 0.522 |
AST, U/L | 62 (42–89) | 65 (42–108) | 62 (42–84) | 0.254 | 72 (45–137) | 61 (38–84) | 0.060 |
ALT, U/L | 106 (68–167) | 121 (75–211) | 102 (62–153) | 0.098 | 124 (79–216) | 99 (68–154) | 0.111 |
Total bilirubin, mg/dL | 0.8 (0.7–1.0) | 0.8 (0.7–1.1) | 0.8 (0.6–1.0) | 0.114 | 1.0 (0.7–1.2) | 0.8 (0.6–1.0) | 0.018 |
Platelet, 109/L | 190 (155–224) | 198 (160–231) | 183 (154–218) | 0.141 | 190.8 ± 46.7 | 194.6 ± 45.7 | 0.676 |
qHBsAg, log IU/mL | 3.8 ± 0.7 | 4.0 ± 0.6 | 3.7 ± 0.8 | 0.009 | 4.0 ± 0.6 | 3.8 ± 0.8 | 0.182 |
HBV DNA, log IU/mL | 7.7 (6.8–8.3) | 7.9 (7.1–8.3) | 7.5 (6.5–8.1) | 0.165 | 7.6 ± 1.0 | 7.4 ± 1.3 | 0.259 |
Antiviral treatment | 0.676 | 0.961 | |||||
LAM | 75 (38.3) | 40 (42.6) | 35 (34.3) | 24 (42.9) | 22 (39.3) | ||
ADV | 2 (1.0) | 1 (1.1) | 1 (1.0) | 1 (1.8) | 1 (1.8) | ||
LdT | 46 (23.5) | 23 (24.5) | 23 (22.5) | 12 (21.4) | 15 (26.8) | ||
ETV | 61 (31.1) | 25 (26.6) | 36 (35.3) | 16 (28.6) | 16 (28.6) | ||
TDF | 12 (6.1) | 5 (5.3) | 7 (6.9) | 3 (5.4) | 2 (3.6) | ||
Treatment duration, m | 24.3 (12.2–36.8) | 24.3 (12.2–36.5) | 23.7 (12.1–36.6) | 0.306 | 23.8 (12.2–36.5) | 24.3 (12.1–36.6) | 0.835 |
Follow-up, m | 54.9 (31.3–99.3) | 59.6 (33.7–102.9) | 45.2 (30.7–94.2) | 0.145 | 55.1 (26.1–103.2) | 50.9 (31.9–92.7) | 0.979 |
Treatment response | |||||||
HBeAg seroclearance | 110 (56.1) | 54 (57.4) | 56 (54.9) | 0.830 | 30 (53.6) | 28 (50) | 0.850 |
Virological response | 115 (58.7) | 50 (53.2) | 65 (63.7) | 0.177 | 28 (50) | 32 (57.1) | 0.570 |
Age at e seroclearance | 42.1 ± 11.7 | 38.5 ± 11.4 | 45.6 ± 11.0 | 0.001 | 41.5 ± 11.1 | 41.4 ± 10.2 | 0.959 |
Time to seroclearance, m | 17.5 (9.3–34.8) | 17.8 (8.9–28.6) | 16.9 (9.4–39.9) | 0.401 | 23.9 (15.4–38.8) | 29.4 (16.0–45.5) | 0.436 |
HBeAg reversiona | 13 (11.8) | 4 (7.4) | 9 (16.1) | 0.266 | 2 (6.7) | 3 (10.7) | 0.665 |
HBeAg(−) hepatitisa | 35 (31.8) | 15 (27.8) | 20 (35.7) | 0.491 | 9 (30) | 10 (35.7) | 0.854 |
HBsAg seroclearance | 8 (4.1) | 4 (4.3) | 4 (3.9) | 1.000 | 2 (3.6) | 4 (7.1) | 0.679 |